Drug-Eluting Stent Thrombosis. The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited

JACC: Cardiovascular Interventions

Volumn 2, Issue 7, 2009, Pages 583-593

  Chen, Jack P ^a   Hou, Dongming ^a   Pendyala, Lakshmana ^a   Goudevenos, John A ^b   Kounis, Nicholas G ^c  

^a Saint Joseph's Heart and Vascular Institute   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

^c Patras Highest Institute of Education and Technology   (Greece)

Author keywords

allergic reaction; drug eluting stent; hypersensitivity; Kounis; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CHEMOKINE; CHYMASE; CILOSTAZOL; CLOPIDOGREL; CYTOKINE; HISTAMINE; LEUKOTRIENE; THIENOPYRIDINE DERIVATIVE; THROMBOXANE; TICLOPIDINE; TRYPTASE;

ACUTE CORONARY SYNDROME; ALLERGIC REACTION; ANAPHYLAXIS; BARE METAL STENT; CARDIOVASCULAR RISK; CELL INFILTRATION; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DISEASE COURSE; DRUG ELUTING STENT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ENDOTHELIAL DYSFUNCTION; EOSINOPHIL; EQUIPMENT DESIGN; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; IN-STENT RESTENOSIS; LYMPHOCYTE; MACROPHAGE; MAST CELL; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; PLASMA CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THROMBOGENESIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG HYPERSENSITIVITY; DRUG-ELUTING STENTS; HUMANS; HYPERSENSITIVITY; METALS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT FAILURE;

EID: 67650673809     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.04.017     Document Type: Review

References (71)

1. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
2. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
3. Camenzind E. Address at Joint Session of the European Society of Cardiology and the World Heart Federation 2006. Barcelona, Spain.
4. U.S. Food and Drug Administration CDRH. Update to FDA Statement on Coronary Drug-Eluting Stents (2007). http://www.fda.gov/cdrh/news/010407.html Accessed June 8, 2008
5. Lemos P.A., Serruys P.W., van Domburg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'real world': the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
6. Ellis S.G., Colombo A., Grube E., et al. Incidence, timing and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
7. Pfisterer M., Brunner-La R.H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
8. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
9. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
10. Bavry A.A., Kumbhani D.J., Helton T., et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
11. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
12. Chen J.P., and Jabara R. Very late drug-eluting stent thrombosis and cardiogenic shock: 1,249 days after implantation. J Invasive Cardiol 19 (2007) E381-E384
13. Kedia G., and Lee M.S. Stent thrombosis with drug-eluting stents: a re-examination of the evidence. Cathet Cardiovasc Interv 69 (2007) 782-789
14. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
15. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
16. Zhao F.H., Chen Y.D., Jin Z.N., et al. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?. Med Hypotheses 70 (2008) 512-514
17. Chen J.P., Crisco L.V.T., Jabara R., and King III S.B. Late Angiographic Stent Thrombosis: the LAST straw for drug-eluting stents?. Angiology 59 (2009) 676-681
18. Shinke T., Li J., Chen J.P., et al. High incidence of intramural thrombus after overlapping paclitaxel-eluting stents: correlated angioscopic and histopathologic analysis in porcine coronary arteries. Circ Cardiovasc Interv 1 (2008) 28-35
19. Pendyala L., Li J., Shinke T., et al. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with paclitaxel-eluting stents is associated with inflammation and oxidative stress. J Am Coll Cardiol Intv 2 (2009) 253-262
20. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
21. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
22. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
23. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
24. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 114 (2006) e600-e606
25. Lee S.W., Park S.W., Hong M.K., et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
26. Kounis N.G., and Zavras G.M. Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 45 (1991) 121-128
27. Nikolaidis L.A., Kounis N.G., and Grandman A.H. Allergic angina and allergic myocardial infarction: a new twist on an old syndrome. Can J Cardiol 18 (2002) 508-511
28. Soufras G.D., Ginopoulos P.V., Papadaki P.J., et al. Penicillin allergy in cancer patients manifesting as Kounis syndrome. Heart Vessels 20 (2005) 159-163
29. Kawano H., Koide Y., Baba T., et al. Granulation tissue with eosinophil infiltration in the restenotic lesion after coronary stent implantation. Circulation J 68 (2004) 722-723
30. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
31. Bennett C.L., Nebeker J.R., Lyons E.A., et al. The research on adverse drug events and reports (RADAR) project. JAMA 293 (2005) 2131-2140
32. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
33. Azarbal B., and Currier J.W. Allergic reactions after the implantation of drug-eluting stents. J Am Coll Cardiol 47 (2006) 182-183
34. Kounis N.G. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm?. Int J Cardiol 110 (2006) 7-14
35. Kounis N.G., and Zavras G.M. Allergic angina and allergic myocardial infarction. Circulation 94 (1996) 1789
36. Zanotti K.M., and Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety 24 (2001) 767-777
37. Sevelda P., Mayerhofer K., Obermair A., et al. Thrombosis with paclitaxel. Lancet 343 (1994) 727
38. Hekmat E. Fatal myocardial infarction potentially induced by paclitaxel. Ann Pharmacotherapy 30 (1996) 1110-1112
39. Laher S., and Karp S.J. Acute myocardial infarction following paclitaxel administration for ovarian carcinoma. Clin Oncol 9 (1997) 124-126
40. Henry A., Charpiat B., Perol M., et al. Possible anaphylactic reaction to Taxus stent: a case report. Catheter Cardiovasc Interv 66 (2005) 554-556
41. Kim J.W., Park C.G., Seo H.S., et al. Delayed severe multivessel spasm and aborted sudden death after Taxus stent implantation. Heart 91 (2005) e15
42. Revell P.A., Braden M., and Freeman M.A. Review of the biological response to a novel bone cement containing poly(ethyl methacrylate) and n-butyl methacrylate. Biomaterials 19 (1998) 1579-1586
43. Niemi S.M., Fox J.G., Brown L.R., et al. Evaluation of ethylenevinyl acetate copolymer as a non-inflammatory alternative to Freund's complete adjuvant in rabbits. Lab Anim Sci 35 (1985) 609-612
44. Oppei T., and Schnuch A. The most frequent allergens in allergic contact dermatitis. Deutsch Med Wochennschr 131 (2006) 1584-1589
45. Wertman B., Azarbal B., Riedl M., et al. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 47 (2006) 1226-1227
46. Fukahara K., Minami K., Reiss N., et al. Systemic allergic reactions to the percutaneous patent foramen ovale closure. J Thoracic Cardiovasc Surg 125 (2003) 213-214
47. Dasika U.K., Kanter K.R., and Vincent R. Nickel allergy to percutaneous patent foramen ovale occluder and subsequent systemic nickel allergy. J Thoracic Cardiovasc Surg 125 (2003) 2112-2113
48. Sharifi M., and Burks J. Efficacy of clopidogrel in the treatment of post-ASD closure migraines. Catheter Cardiovasc Interv 63 (2004) 255
49. Iijima R., Ikari Y., Amiya E., et al. The impact of metallic allergy on stent implantation: metal allergy and recurrence of in-stent thrombosis. Int J Cardiol 104 (2005) 319-325
50. Svedman C., Tillman C., Gustavsson C.G., et al. Contact allergy to gold in patients with gold-plated intracoronary stents. Contact Dermatitis 52 (2005) 192-196
51. Mosseri M., Tamari I., Plich M., et al. Short- and long-term outcomes of the titanium-NO stent registry. Cardiovasc Revasc Med 6 (2005) 2-6
52. Kounis N.G., Kounis G.N., Kouni S.N., et al. Allergic reactions following implantation of drug-eluting stents: a manifestation of Kounis syndrome?. J Am Coll Cardiol 48 (2006) 592-593
53. Kounis N.G., Kourelis T., Hahalis G., Manola A., and Theoharides T.C. Kounis syndrome (allergic angina and allergic myocardial infarction). In: Gallo A.P. (Ed). Angina Pectoris (2008), Nova Biomedical Books, New York, NY 76-150
54. Kounis N.G., Kouni S.N., and Koutsojannis C.M. Myocardial infarction after aspirin treatment, and Kounis syndrome. J R Soc Med 98 (2005) 296
55. Miyazaki D., Nakamura T., Toda M., Cheung-Chau K.W., Richardson R.M., and Ono S.J. Macrophage inflammatory protein-1 as a constimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J Clin Invest 115 (2005) 434-442
56. Gollapudi R.R., Teirstein P.S., Stevenson D.D., and Simon R.A. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292 (2004) 3017-3023
57. Plavix (clopidogrel bisulfate). [package insert] (2006), Bristol-Myers Squibb Company & Sanofi-Synthelabo, New York, NY revised May
58. Von Tiehl K.F., Price M.J., Valencia R., Ludington K.J., Teirstein P.S., and Simon R.A. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 50 (2007) 2039-2043
59. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., et al. Down-regulation of FcεRI expression in human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997) 1438-1445
60. Simpson A., Soderstrom L., Ahlstedt S., Murray C.S., Wooddcock A., and Custovic A. IgE antibody quantification and the probability of wheeze in preschool children. J Allergy Clin Immunol 116 (2005) 744-749
61. Nopp A., Johansson S.G.O., Lundberg M., and Oman H. Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 61 (2006) 1366-1368
62. Von Hundelshausen P., and Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100 (2007) 27-40
63. Gawaj M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378-3384
64. Ramade S.V., Miller K.M., Richard R.E., Chan A.K., Allen M.J., and Helmus M.N. Physical characterization of controlled release of paclitaxel from the TAXUS Express drug eluting stent. J Biomed Mater Res 71A (2004) 625-634
65. Hwang C.W., Wu D., and Edelman E.R. Physiologic transport forces govern drug distribution for stent-based delivery. Circulation 104 (2001) 600-605
66. Vetrovec G.V., Rizik D., Williard C., Snead D., Piotrovski V., and Kopia G. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv 67 (2006) 32-37
67. Tesfamariam B. Local vascular toxicokinetics of stent-based drug delivery. Toxicol Lett 168 (2007) 93-102
68. Descotes J., and Choquet-Kastylevsky G. Gell and Coombs's classification: is it still valid?. Toxicology 58 (2001) 43-49
69. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
70. Nemmar A., Hoet P.H.M., Vermylen J., et al. Pharmacological stabilization of mast cells abrogates late thrombotic events induced by diesel exhaust particles in hamsters. Circulation 110 (2004) 1670-1677
71. Bavry A.A., Kumbhani D.J., Helton T.J., and Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?. A meta-analysis. J Am Coll Cardiol 45 (2005) 941-946